■这项研究的目的是调查体重指数(BMI)和体重对替格瑞洛和替格瑞洛代谢物浓度的影响,AR-C124910XX,以及中国汉族人群不稳定型心绞痛(UA)的血小板聚集率(PAR)。具体来说,在服用包括阿司匹林和替格瑞洛的双联抗血小板治疗(DAPT)后,主要关注这些参数.
■共105例UA患者纳入研究。测定二磷酸腺苷(PAR-ADP)诱导的血小板聚集率,以及DAPT治疗后3天和30天。在DAPT治疗后3天和30天检测替格瑞洛和AR-C124910XX的血浆浓度。我们进行了相关分析,以评估BMI和体重对替格瑞洛和AR-C124910XX浓度的影响。在PAR-ADP上,以及在DAPT治疗后3天和30天抑制二磷酸腺苷(IPA-ADP)诱导的血小板聚集。
■BMI和体重与基线PAR-ADP呈正相关(r=0.205,p=0.007;r=0.122,p=0.022)。DAPT治疗后3天和30天的PAR-ADP显着低于基线(61.56%±10.62%,8.02%±7.52%,12.90%±7.42%,p<0.001)。DAPT治疗后3天,体重与替格瑞洛和AR-C124910XX的浓度呈负相关(r=-0.276,p<0.001;r=-0.337,p<0.001)。此外,BMI与替格瑞洛和AR-C124910XX的浓度呈相似的负相关(r=-0.173,p=0.009;r=-0.207,p=0.002)。治疗后30天,体重和BMI均与替格瑞洛(r=-0.256,p<0.001;r=-0.162,p=0.015)及其代谢产物(r=-0.352,p<0.001;r=-0.202,p=0.002)呈负相关。治疗后30d体重与PAR-ADP呈正相关(r=0.171,p=0.010),与IPA-ADP呈负相关(r=-0.163,p=0.015)。同样,BMI与PAR-ADP呈正相关(r=0.217,p=0.001),与IPA-ADP呈负相关(r=-0.211,p=0.001)。
■BMI和体重是影响替格瑞洛在中国汉族UA患者接受包括替格瑞洛在内的DAPT治疗后的药代动力学和药效学的关键因素。在基线和DAPT治疗后30天,BMI和体重均与PAR-ADP呈正相关。
■ChiCTR2100044938,https://www.chictr.org.cn/.
UNASSIGNED: The aim of this study was to investigate the impact of body mass index (BMI) and body weight on the concentrations of
ticagrelor and the
ticagrelor metabolite, AR-C124910XX, as well as the platelet aggregation rate (PAR) in a Chinese Han population with unstable angina (UA). Specifically, it focused on these parameters following the administration of dual antiplatelet therapy (DAPT) comprising aspirin and
ticagrelor.
UNASSIGNED: A total of 105 patients with UA were included in the study. Measurement of the platelet aggregation rate induced by adenosine diphosphate (PAR-ADP) was performed before, as well as 3 and 30 days after DAPT treatment. The plasma concentrations of ticagrelor and AR-C124910XX were detected at 3 and 30 days after DAPT treatment. We conducted correlation analyses to assess the effects of BMI and body weight on the concentrations of ticagrelor and AR-C124910XX, on PAR-ADP, and on the inhibition of platelet aggregation induced by adenosine diphosphate (IPA-ADP) at both 3 and 30 days after DAPT treatment.
UNASSIGNED: The BMI and body weight were positively correlated with baseline PAR-ADP (r = 0.205, p = 0.007; r = 0.122, p = 0.022). The PAR-ADP at 3 and 30 days after DAPT treatment were significantly lower than at baseline (61.56% ± 10.62%, 8.02% ± 7.52%, 12.90% ± 7.42%, p < 0.001). There was a negative correlation between body weight and the concentrations of ticagrelor and AR-C124910XX at 3 days following DAPT treatment (r = -0.276, p < 0.001; r = -0.337, p < 0.001). Additionally, BMI showed a similar negative correlation with the concentrations of ticagrelor and AR-C124910XX (r = -0.173, p = 0.009; r = -0.207, p = 0.002). At 30 days after treatment, both body weight and BMI were negatively correlated with
ticagrelor (r = -0.256, p < 0.001; r = -0.162, p = 0.015) and its metabolite (r = -0.352, p < 0.001; r = -0.202, p = 0.002). Body weight was positively correlated with PAR-ADP (r = 0.171, p = 0.010) and negatively correlated with IPA-ADP (r = -0.163, p = 0.015) at 30 days after treatment. Similarly, BMI was positively correlated with PAR-ADP (r = 0.217, p = 0.001) and negatively correlated with IPA-ADP (r = -0.211, p = 0.001) at the same time point.
UNASSIGNED: BMI and body weight are key factors influencing the pharmacokinetics and pharmacodynamics of ticagrelor in Chinese Han patients with UA following DAPT treatment that includes
ticagrelor. Both BMI and body weight were positively correlated with PAR-ADP at baseline and 30 days after DAPT treatment.
UNASSIGNED: ChiCTR2100044938, https://www.chictr.org.cn/.